CA1128859A - Tissue adhesive - Google Patents
Tissue adhesiveInfo
- Publication number
- CA1128859A CA1128859A CA344,717A CA344717A CA1128859A CA 1128859 A CA1128859 A CA 1128859A CA 344717 A CA344717 A CA 344717A CA 1128859 A CA1128859 A CA 1128859A
- Authority
- CA
- Canada
- Prior art keywords
- fibrinogen
- tissue adhesive
- set forth
- inhibitor
- cryoprecipitate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Abstract
ABSTRACT OF THE DISCLOSURE:
A tissue adhesive on the basis of human or animal pro-tein contains factor XIII and at least 33 % by weight of fibrinogen, has a ratio of factor XIII to fibrinogen, ex-pressed in units of factor XIII per gram of fibrinogen, of at least 80, contains fibrinogen and albumin in the overall protein at a ratio of 33 to 90 : 5 to 40, contains plasmino-gen-activator-inhibitor or plasmin inhibitor in an amount of 250 to 25,000 KIU per g of fibrinogen and has been lyophilized.
A tissue adhesive on the basis of human or animal pro-tein contains factor XIII and at least 33 % by weight of fibrinogen, has a ratio of factor XIII to fibrinogen, ex-pressed in units of factor XIII per gram of fibrinogen, of at least 80, contains fibrinogen and albumin in the overall protein at a ratio of 33 to 90 : 5 to 40, contains plasmino-gen-activator-inhibitor or plasmin inhibitor in an amount of 250 to 25,000 KIU per g of fibrinogen and has been lyophilized.
Description
1~8~
The invention relates to a tissue adhesive on the basis of human or animal proteins, containing fibrinogen and factor XIII.
It has been known for long to use blood coagulating substances for stopping bleedings and for sealing wounds.
According to the first proposals of this kind, fibrin tampons and fibrin platelets, respectively, were used.
During the Second World War, tissue adherences by means of blood plasma were suggested.
In recent times, a tissue adhesive on the basis of fibrinogen and factor XIII for seamless interfascicular nerve transplantations in animal experiments has been described by H. Matras et al. in "Wiener Medizinischen Wochenschrift", 1972, page 517.
A further study was carried out by Spangler et al.
in "Wiener Klinischen Wochenschrift", 1973, pages 1 to 7.
Also there, the possibility was shown in animal experiments of carrying out a tissue adherence with the aid of fibri-nogen as a cryoprecipitate and thrombin.
The known preparatlons have not yet proved satis-factory, since they do not sufficiently meet the demands set to a tissue adhesive, i.e.
a) high straining capacity of the adherences and wound sealings as well as safe and permanent blood stopping, i.e. good adhering capacity of the adhesive to the wound and tissue surfaces, as well as hi~h internal strength of the same, ; b) controllable durability of the adherences in the body, c) complete absorbability of the adhesive in the course 3~
8~3S~
of the wound healing process, (d) wound healing stimulating properties.
This may partly be due to the fact that, in the known preparat-ions the coagulation factors necessary for blood stopping have not been present in an optimal proportion to one another, and also to the fact that the fibrinolytic activity in the area of adher-ence has not been sufficiently under control. Premature disso-lutions of the tissue adherences frequently occurred due to enzymatic influence.
The invention aims at avoiding these disadvantages and difficulties and has as its object to provide a lyophilized tissue adhesive of human or animal origin, which meets the demandsset out further above and which is present in a lyophili-zed form, which is desir~d for its longer durability and better transporting and storing properties.
Accordingly, the invention provides a tissue adhesive on the basis of human or animal proteins and containing fibrino-gen and factor XIII, which tissue adhesive is characterized in that (a) it contains at least 33% by weight of fibrinogen, (b)- the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen, amounts to at least 80, (c) fibrinogen and albumin are contained in the total protein at a ratio of 33 to 90 : 5 to ~0, (d) it has a content of plasminogen-activator-inhibitor or plasmin-inhibitor, preferably aprotinin, in an amount of 250 to 25,000 Kallikrein-inactivator-units (KIU) per gram of fibrinogen, (e) the preparation has been lyophilized.
According to a preferred embodiment the tissue adhe-~L%88~i~
sive additionally contains glycine, whereby the resolubility of the lyophilized product is improved.
Furthermore, the tissue adhesive additionally may contain glucose or sucrose, which components also improve the solubility.
The tissue adhesive furthermore may contain 0.2 to 200 International Units (IU) of heparin per gram of fibrinogen, whereby a stabilizing effect is obtained.
The tissue adhesive according to the invention posses-ses characteristic cross-linking prop~ertiés after the dis-solution, which are determinable by the sodium-dodecyl-sul-phate-(SDS)-polyacrylamide-gel-electrophoresis method. The test is carried out in that, after mixing of the tissue ad-hesive with an equal volume of a solution containing 40 ~Moles of CaCl2 and 15 NIH-units (U.S. National Institute of Health units) of thrombin per ml, the mixture is incu-bated at 37C. The cross-linking degree is determined by a gel electrophoresis after stopping of the reaction and reductive splitting of the disulphide bridges contained in the proteins by the addition of a mixture of urea, sodium dodecyl sulphate and ~-mercaptoethanol. Typical of the tissue adhesive according to the invention is a complete cross-linking of the fibrin-~-chains after 3 to 5 minutes, and a cross-linking of at least 35 ~ of the fibrin-~ chains a ter two hours.
Fibrinogen, albumin and cold-insoluble globulin, in the total protein, are to be present in the tissue adhesive ac-cording to the invention at a certain ratio; this ratio amounts to 33 to 90 : 5 to 40 : 0.2 to 15.
The invention moreover comprises a method of producing 81~S~3 the tissue adhesive described from plasma cryoprecipitate, which method comprises:
removing from the cryoprecipitate plasma-protein that is soluble in the cold, by treating the cryoprecipitate with a buffer solution containing sodium citrate, sodium chloride, glycine, glucose, a plasminogen-activator-inhibitor or plasmin-inhibitor, and h~parin, dissolving the purified precipitate, adding human albumin, and lyophilizing the resulting solution.
Advantageously, the cryoprecipitate has been produced of human or animal fresh plasma frozen at -20C. When in-creasing the temperature to 0 to 2C the cryoprecipitate is gained and separated by centrifugation. The precipitate is eluted by a single or repeated elution with the buffer solution having a pH of 6 to 8.0, and centrifuged at 0 to 4C in order to remove the plasma-protein that is soluble in the cold. The treat-ment with the buffer solution is carried out until the desired factor-XIII-fibrinogen ratio is reached.
The purified precipitate is dissolved with a further buffer solution containing human albumin, glycine and, if desired, glucose or sucrose, a plasminogen-activator-inhibitor or plasmin inhibitor as well as heparin, and having a pH of 6.5 to 9.0, and is diluted to a protein concentration of 4.~0 to 9.0 ~. The solution is filtered through a membrane filter having a pore size of down to 0.2 )um, filled into final containers and lyophilized.
The lyophilized tissue adhesive thus obtained can be stored at room temperature or preferably at ~4C; it is ready for use after reconstitution with aqua ad iniectabilia, to which~
if desired, a plasminogen-activator-inhibitor , . ~
,,, l ~1~8~5~
or a plasmin inhibitor, preferably aprotinin, can be added.
When dissolving the lyophilized preparation, attention has to be paid that the solution ready for use contains at least 70 mg of fibrinogen per ml.
The tissue adhesive according to the invention can be applied universally. It can be used for seamless connection of human or animal tissue or organ parts, for sealing wounds and stopping bleedings as well as for stimulating wound healings.
Preferred fields of application in which the tissue adhesive can be successfully used are: indications in the field of ear, nose and throat surgery, oral surgery, dentistry, neurosurgery, plastic surger~7, general sur~ery, abdominal surgery, thorax and vascular surgery, orthopaedics, accident surgery, urology, ophthalmology and gynaecology.
Advantageously,a mixture of thrombin and calcium chloride is added to the adhesive prior to the application of the tissue adhesive according to the invention or is applied onto the tissues to be connected.
The method of the lnvention is explained in more detail by way of the following example:
21 l of human plasma, which had been frozen at -20C, were heated to +2C. The resulting cryoprecipitate (435 ~) was separated by centrifugation at +2C and treated at +2C
with 4.3 l of a buffer solution adjusted at a pH of 6.5 and containing 6.6 g of Na3-citrate.2H20, 3.4 g of NaCl, 10.0 g of glycine, 13.0 of glucose.1H20~ 50,000 KIU of aprotinin and 200 IU of heparin per l, and again centrifuged at +2C.
The separated precipitate was dissolved in a further buffer 3G solution having a pH of 7.9 and containing 35.0 g of human ~z~
albumin, 20.0 g of glycine, 50,000 ~IU of aprotinin and 200 IU of heparin per l, and diluted to a concentration of 70 mg of protein per ml.
Then the solution was sterilized by filtration through membrane filters having a pore size of down to 0.2 ~m, fill-ed into final containers at 2.2 ml each, deepfrozen and lyo-philized. After reconstitution of the lyophilized product to a fibrinogen concentration of ~0 mg/ml, the tissue adhesive preparation ready for use showed, in the cross-linking test, complete fibrin-~-cross-linking after S minutes and 66 %
fibrin-~-cross-linking after 2 hours at 37C.
The ratio of the proteins fibrinogen to albumin to cold-insoluble globulin, contained in the tissue adhesive, was determined to be 64.0 : 22.3 : 7.7. The heparin content was 4.5 IU per g of fibrinogen. Aprotinin was contained at a concentration of 1,133 KIU per g of fibrinogen. The con-tent of factor XIII amounted to 161 units per g of fibrino-gen. The total protein content in the lyophilized prepara-t~on was 72.2 %, the content of fibrinogen in the lyophilized preparation was 46.2 %.
The determinations were carried out in the following manner: The determination of the factor-XIII-units was per-formed by means of a cross-linking test, in which factor-XIII-free fibrinogen was used as a substrate and the fibrin cross-linking caused by the addition of the unknown diluted sample served as a measure for the amount of factor XIII
contained therein~ A corresponding calibration curve was obtained with pooled human citrate plasma, 1 ml plasma con-taining 1 unit of factor XIII per definitionem. The quanti-tative protein determinations were carried out by the method ~1~8~5~
according to Kjeldahl.
The determination of the proteins relative to oneanother was also performed by the SDS-polyacrylamide-gel-electrophoresis method, i.e. a) with a non-reduced sample of the tissue adhesive and b) with a sample reduced with ~-mercaptoethanol.
The invention relates to a tissue adhesive on the basis of human or animal proteins, containing fibrinogen and factor XIII.
It has been known for long to use blood coagulating substances for stopping bleedings and for sealing wounds.
According to the first proposals of this kind, fibrin tampons and fibrin platelets, respectively, were used.
During the Second World War, tissue adherences by means of blood plasma were suggested.
In recent times, a tissue adhesive on the basis of fibrinogen and factor XIII for seamless interfascicular nerve transplantations in animal experiments has been described by H. Matras et al. in "Wiener Medizinischen Wochenschrift", 1972, page 517.
A further study was carried out by Spangler et al.
in "Wiener Klinischen Wochenschrift", 1973, pages 1 to 7.
Also there, the possibility was shown in animal experiments of carrying out a tissue adherence with the aid of fibri-nogen as a cryoprecipitate and thrombin.
The known preparatlons have not yet proved satis-factory, since they do not sufficiently meet the demands set to a tissue adhesive, i.e.
a) high straining capacity of the adherences and wound sealings as well as safe and permanent blood stopping, i.e. good adhering capacity of the adhesive to the wound and tissue surfaces, as well as hi~h internal strength of the same, ; b) controllable durability of the adherences in the body, c) complete absorbability of the adhesive in the course 3~
8~3S~
of the wound healing process, (d) wound healing stimulating properties.
This may partly be due to the fact that, in the known preparat-ions the coagulation factors necessary for blood stopping have not been present in an optimal proportion to one another, and also to the fact that the fibrinolytic activity in the area of adher-ence has not been sufficiently under control. Premature disso-lutions of the tissue adherences frequently occurred due to enzymatic influence.
The invention aims at avoiding these disadvantages and difficulties and has as its object to provide a lyophilized tissue adhesive of human or animal origin, which meets the demandsset out further above and which is present in a lyophili-zed form, which is desir~d for its longer durability and better transporting and storing properties.
Accordingly, the invention provides a tissue adhesive on the basis of human or animal proteins and containing fibrino-gen and factor XIII, which tissue adhesive is characterized in that (a) it contains at least 33% by weight of fibrinogen, (b)- the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen, amounts to at least 80, (c) fibrinogen and albumin are contained in the total protein at a ratio of 33 to 90 : 5 to ~0, (d) it has a content of plasminogen-activator-inhibitor or plasmin-inhibitor, preferably aprotinin, in an amount of 250 to 25,000 Kallikrein-inactivator-units (KIU) per gram of fibrinogen, (e) the preparation has been lyophilized.
According to a preferred embodiment the tissue adhe-~L%88~i~
sive additionally contains glycine, whereby the resolubility of the lyophilized product is improved.
Furthermore, the tissue adhesive additionally may contain glucose or sucrose, which components also improve the solubility.
The tissue adhesive furthermore may contain 0.2 to 200 International Units (IU) of heparin per gram of fibrinogen, whereby a stabilizing effect is obtained.
The tissue adhesive according to the invention posses-ses characteristic cross-linking prop~ertiés after the dis-solution, which are determinable by the sodium-dodecyl-sul-phate-(SDS)-polyacrylamide-gel-electrophoresis method. The test is carried out in that, after mixing of the tissue ad-hesive with an equal volume of a solution containing 40 ~Moles of CaCl2 and 15 NIH-units (U.S. National Institute of Health units) of thrombin per ml, the mixture is incu-bated at 37C. The cross-linking degree is determined by a gel electrophoresis after stopping of the reaction and reductive splitting of the disulphide bridges contained in the proteins by the addition of a mixture of urea, sodium dodecyl sulphate and ~-mercaptoethanol. Typical of the tissue adhesive according to the invention is a complete cross-linking of the fibrin-~-chains after 3 to 5 minutes, and a cross-linking of at least 35 ~ of the fibrin-~ chains a ter two hours.
Fibrinogen, albumin and cold-insoluble globulin, in the total protein, are to be present in the tissue adhesive ac-cording to the invention at a certain ratio; this ratio amounts to 33 to 90 : 5 to 40 : 0.2 to 15.
The invention moreover comprises a method of producing 81~S~3 the tissue adhesive described from plasma cryoprecipitate, which method comprises:
removing from the cryoprecipitate plasma-protein that is soluble in the cold, by treating the cryoprecipitate with a buffer solution containing sodium citrate, sodium chloride, glycine, glucose, a plasminogen-activator-inhibitor or plasmin-inhibitor, and h~parin, dissolving the purified precipitate, adding human albumin, and lyophilizing the resulting solution.
Advantageously, the cryoprecipitate has been produced of human or animal fresh plasma frozen at -20C. When in-creasing the temperature to 0 to 2C the cryoprecipitate is gained and separated by centrifugation. The precipitate is eluted by a single or repeated elution with the buffer solution having a pH of 6 to 8.0, and centrifuged at 0 to 4C in order to remove the plasma-protein that is soluble in the cold. The treat-ment with the buffer solution is carried out until the desired factor-XIII-fibrinogen ratio is reached.
The purified precipitate is dissolved with a further buffer solution containing human albumin, glycine and, if desired, glucose or sucrose, a plasminogen-activator-inhibitor or plasmin inhibitor as well as heparin, and having a pH of 6.5 to 9.0, and is diluted to a protein concentration of 4.~0 to 9.0 ~. The solution is filtered through a membrane filter having a pore size of down to 0.2 )um, filled into final containers and lyophilized.
The lyophilized tissue adhesive thus obtained can be stored at room temperature or preferably at ~4C; it is ready for use after reconstitution with aqua ad iniectabilia, to which~
if desired, a plasminogen-activator-inhibitor , . ~
,,, l ~1~8~5~
or a plasmin inhibitor, preferably aprotinin, can be added.
When dissolving the lyophilized preparation, attention has to be paid that the solution ready for use contains at least 70 mg of fibrinogen per ml.
The tissue adhesive according to the invention can be applied universally. It can be used for seamless connection of human or animal tissue or organ parts, for sealing wounds and stopping bleedings as well as for stimulating wound healings.
Preferred fields of application in which the tissue adhesive can be successfully used are: indications in the field of ear, nose and throat surgery, oral surgery, dentistry, neurosurgery, plastic surger~7, general sur~ery, abdominal surgery, thorax and vascular surgery, orthopaedics, accident surgery, urology, ophthalmology and gynaecology.
Advantageously,a mixture of thrombin and calcium chloride is added to the adhesive prior to the application of the tissue adhesive according to the invention or is applied onto the tissues to be connected.
The method of the lnvention is explained in more detail by way of the following example:
21 l of human plasma, which had been frozen at -20C, were heated to +2C. The resulting cryoprecipitate (435 ~) was separated by centrifugation at +2C and treated at +2C
with 4.3 l of a buffer solution adjusted at a pH of 6.5 and containing 6.6 g of Na3-citrate.2H20, 3.4 g of NaCl, 10.0 g of glycine, 13.0 of glucose.1H20~ 50,000 KIU of aprotinin and 200 IU of heparin per l, and again centrifuged at +2C.
The separated precipitate was dissolved in a further buffer 3G solution having a pH of 7.9 and containing 35.0 g of human ~z~
albumin, 20.0 g of glycine, 50,000 ~IU of aprotinin and 200 IU of heparin per l, and diluted to a concentration of 70 mg of protein per ml.
Then the solution was sterilized by filtration through membrane filters having a pore size of down to 0.2 ~m, fill-ed into final containers at 2.2 ml each, deepfrozen and lyo-philized. After reconstitution of the lyophilized product to a fibrinogen concentration of ~0 mg/ml, the tissue adhesive preparation ready for use showed, in the cross-linking test, complete fibrin-~-cross-linking after S minutes and 66 %
fibrin-~-cross-linking after 2 hours at 37C.
The ratio of the proteins fibrinogen to albumin to cold-insoluble globulin, contained in the tissue adhesive, was determined to be 64.0 : 22.3 : 7.7. The heparin content was 4.5 IU per g of fibrinogen. Aprotinin was contained at a concentration of 1,133 KIU per g of fibrinogen. The con-tent of factor XIII amounted to 161 units per g of fibrino-gen. The total protein content in the lyophilized prepara-t~on was 72.2 %, the content of fibrinogen in the lyophilized preparation was 46.2 %.
The determinations were carried out in the following manner: The determination of the factor-XIII-units was per-formed by means of a cross-linking test, in which factor-XIII-free fibrinogen was used as a substrate and the fibrin cross-linking caused by the addition of the unknown diluted sample served as a measure for the amount of factor XIII
contained therein~ A corresponding calibration curve was obtained with pooled human citrate plasma, 1 ml plasma con-taining 1 unit of factor XIII per definitionem. The quanti-tative protein determinations were carried out by the method ~1~8~5~
according to Kjeldahl.
The determination of the proteins relative to oneanother was also performed by the SDS-polyacrylamide-gel-electrophoresis method, i.e. a) with a non-reduced sample of the tissue adhesive and b) with a sample reduced with ~-mercaptoethanol.
Claims (11)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A tissue adhesive on the basis of human or animal pro-teins and containing fibrinogen and factor XIII, which tissue adhesive is characterized in that a) it contains at least 33 % by weight of fibrinogen, b) the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen, amounts to at least 80, c) fibrinogen and albumin are contained in the total protein at a ratio of 33 to 90 : 5 to 40, d) it contains plasminogen-activator-inhibitor or plasmin inhibitor in an amount of 250 to 25,000 KIU per g of fibrinogen, and e) it is lyophilized.
2. A tissue adhesive as set forth in claim 1, wherein the plasminogen-activator-inhibitor or plasmin-inhibitor is aprotinin.
3. A tissue adhesive as set forth in claim 1, further con-taining glycine.
4. A tissue adhesive as set forth in claim 1, further con-taining glucose.
5. A tissue adhesive as set forth in claim 1, further con-taining sucrose.
6. A tissue adhesive as set forth in claim 1, which con-tains 0.2 to 200 IU of heparin per g of fibrinogen.
7. A tissue adhesive as set forth in claim 1 being capable, after dissolution of the lyophilized preparation of com-plete cross-linking of the fibrin-?-chains after 3 to 5 minutes of incubation, and of at least 35 % cross-linking of the fibrin-?-chains after 2 hours of incubation, deter-mined according to the SDS-polyacrylamide-gel-electrophor-esis method.
8. A tissue adhesive as set forth in claim 1, wherein the ratio of fibrinogen to albumin to cold-insoluble globulin in the total protein is 33 to 90 : 5 to 40 : 0.2 to 15.
9. A method of producing a tissue adhesive as set forth in claim 1 from plasma cryoprecipitate, which method com-prises removing from the cryoprecipitate plasma-protein that is soluble in the cold, by treating the cryoprecipitate with a buffer solution containing sodium citrate, sodium chloride, glycine, glucose, a plasminogen-activator-in-hibitor or plasmin-inhibitor, and heparin, dissolving the purified precipitate, adding human albumin, and lyophilizing the resulting solution.
10. A method as set forth in claim 9, wherein the cryopreci-pitate is treated once with said buffer solution.
11. A method as set forth in claim 9, wherein the cryoprecipitate is treated several times with said buffer solution.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT118979A AT359652B (en) | 1979-02-15 | 1979-02-15 | METHOD FOR PRODUCING A TISSUE ADHESIVE |
ATA1189/79 | 1979-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1128859A true CA1128859A (en) | 1982-08-03 |
Family
ID=3508534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA344,717A Expired CA1128859A (en) | 1979-02-15 | 1980-01-30 | Tissue adhesive |
Country Status (14)
Country | Link |
---|---|
US (2) | US4362567A (en) |
JP (1) | JPS55110556A (en) |
AT (1) | AT359652B (en) |
BE (1) | BE881466A (en) |
CA (1) | CA1128859A (en) |
CH (1) | CH649711A5 (en) |
DE (1) | DE3002934C2 (en) |
DK (1) | DK150815B (en) |
ES (1) | ES8101381A1 (en) |
FR (1) | FR2448900A1 (en) |
GB (1) | GB2041942B (en) |
IT (1) | IT1141211B (en) |
NL (1) | NL190714B (en) |
SE (2) | SE453799C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5290918A (en) * | 1993-02-23 | 1994-03-01 | Haemacure Biotech Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation |
US5395923A (en) * | 1993-02-23 | 1995-03-07 | Haemacure-Biotech, Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out" |
Families Citing this family (196)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT359652B (en) * | 1979-02-15 | 1980-11-25 | Immuno Ag | METHOD FOR PRODUCING A TISSUE ADHESIVE |
DE3105624A1 (en) * | 1981-02-16 | 1982-09-02 | Hormon-Chemie München GmbH, 8000 München | MATERIAL FOR SEALING AND HEALING Wounds |
EP0068047B1 (en) | 1981-06-25 | 1986-07-23 | Serapharm GmbH & Co. KG | Enriched plasma derivative for promoting wound sealing and wound healing |
EP0068149A3 (en) * | 1981-06-25 | 1983-07-20 | Serapharm GmbH & Co. KG | Dry preparation containing fibrinogene, its production and use |
US4442655A (en) * | 1981-06-25 | 1984-04-17 | Serapharm Michael Stroetmann | Fibrinogen-containing dry preparation, manufacture and use thereof |
AT369990B (en) * | 1981-07-28 | 1983-02-25 | Immuno Ag | METHOD FOR PRODUCING A TISSUE ADHESIVE |
DE3203775A1 (en) * | 1982-02-04 | 1983-08-11 | Behringwerke Ag, 3550 Marburg | FIBRINOGEN PREPARATION, METHOD FOR THEIR PRODUCTION AND THEIR USE |
DE3214337C2 (en) * | 1982-04-19 | 1984-04-26 | Serapharm - Michael Stroetmann, 4400 Münster | Resorbable flat material for sealing and healing wounds and processes for their manufacture |
US4515637A (en) * | 1983-11-16 | 1985-05-07 | Seton Company | Collagen-thrombin compositions |
JP2648301B2 (en) * | 1983-12-27 | 1997-08-27 | ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド | Vector containing auxiliary DNA for transformation of eukaryotic cells |
US4600574A (en) * | 1984-03-21 | 1986-07-15 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Method of producing a tissue adhesive |
EP0166263A1 (en) * | 1984-05-31 | 1986-01-02 | Green Cross Corporation | Filler composition for filling in defect or hollow portion of bone and kit or set for the preparation of the filler composition |
US4928603A (en) * | 1984-09-07 | 1990-05-29 | The Trustees Of Columbia University In The City Of New York | Method of preparing a cryoprecipitated suspension and use thereof |
US4627879A (en) * | 1984-09-07 | 1986-12-09 | The Trustees Of Columbia University In The City Of New York | Fibrin adhesive prepared as a concentrate from single donor fresh frozen plasma |
AT390001B (en) * | 1984-09-28 | 1990-03-12 | Immuno Ag | METHOD FOR INACTIVATING VARIABLE FILTERABLE DISEASES |
AT382783B (en) * | 1985-06-20 | 1987-04-10 | Immuno Ag | DEVICE FOR APPLICATING A TISSUE ADHESIVE |
JPS6323670A (en) * | 1986-04-25 | 1988-01-30 | バイオ−ポリマ−ズ インコ−ポレ−テツド | Adhesive coating composition and its production |
DE3622642A1 (en) * | 1986-07-05 | 1988-01-14 | Behringwerke Ag | ONE-COMPONENT TISSUE ADHESIVE AND METHOD FOR THE PRODUCTION THEREOF |
DK475386D0 (en) | 1986-10-03 | 1986-10-03 | Weis Fogh Ulla Sivertsen | METHOD AND APPARATUS FOR MANUFACTURING BIOLOGICAL SUBSTANCES |
CH673117A5 (en) * | 1986-12-10 | 1990-02-15 | Ajinomoto Kk | |
US5260420A (en) * | 1987-07-30 | 1993-11-09 | Centre Regional De Transfusion Sanguine De Lille | Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof |
FR2618784B1 (en) * | 1987-07-30 | 1990-04-06 | Lille Transfusion Sanguine | CONCENTRATE OF THROMBIN-COAGULABLE PROTEINS, PROCESS FOR OBTAINING SAME AND ITS USE AS A BIOLOGICAL GLUE |
AT407834B (en) * | 1987-10-08 | 2001-06-25 | Aventis Behring Gmbh | Single-component tissue adhesive and process for its preparation |
ES2064439T3 (en) * | 1988-05-02 | 1995-02-01 | Project Hear | SURGICAL ADHESIVE MATERIAL. |
AT397203B (en) * | 1988-05-31 | 1994-02-25 | Immuno Ag | FABRIC ADHESIVE |
US4837379A (en) * | 1988-06-02 | 1989-06-06 | Organogenesis Inc. | Fibrin-collagen tissue equivalents and methods for preparation thereof |
DE3829524A1 (en) * | 1988-08-31 | 1990-03-01 | Behringwerke Ag | USE OF TRANSGLUTAMINASES AS IMMUNE SUPPRESSIVA |
FR2639958B1 (en) * | 1988-12-06 | 1992-08-21 | Lille Transfusion Sanguine | BIOLOGICAL SUPPORT FOR CELL CULTURES CONSISTING OF PLASMATIC PROTEINS COAGULATED BY THROMBIN, ITS USE FOR THE CULTURE OF KERATINOCYTES, THEIR RECOVERY AND THEIR TRANSPORT FOR THERAPEUTIC USE |
US5226877A (en) * | 1989-06-23 | 1993-07-13 | Epstein Gordon H | Method and apparatus for preparing fibrinogen adhesive from whole blood |
US5209776A (en) * | 1990-07-27 | 1993-05-11 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
US5292362A (en) * | 1990-07-27 | 1994-03-08 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
US5420250A (en) * | 1990-08-06 | 1995-05-30 | Fibrin Corporation | Phase transfer process for producing native plasma protein concentrates |
US5644032A (en) * | 1990-08-06 | 1997-07-01 | Fibrin Corporation | Process for producing fibrinogen concentrates |
US6197325B1 (en) * | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6117425A (en) * | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
US7196054B1 (en) | 1990-11-27 | 2007-03-27 | The American National Red Cross | Methods for treating wound tissue and forming a supplemented fibrin matrix |
EP1142581A3 (en) * | 1990-11-27 | 2002-09-11 | American National Red Cross | Tissue sealant and growth factor containing compositions that promote accelerated wound healing |
US6559119B1 (en) | 1990-11-27 | 2003-05-06 | Loyola University Of Chicago | Method of preparing a tissue sealant-treated biomedical material |
US6093558A (en) * | 1991-07-25 | 2000-07-25 | Edge Biosystems, Inc. | Binding protein of biologically active compositions to an adhesive formulation on a substrate |
EP0602173B1 (en) * | 1991-09-05 | 1999-05-26 | Baxter International Inc. | Topical fibrinogen complex |
WO1993005822A1 (en) * | 1991-09-27 | 1993-04-01 | Octapharma Ag | Tissue glue prepared by using cryoprecipitate |
US5190057A (en) * | 1991-12-13 | 1993-03-02 | Faezeh Sarfarazi | Sarfarazi method of closing a corneal incision |
US5385606A (en) * | 1992-07-06 | 1995-01-31 | Kowanko; Nicholas | Adhesive composition and method |
FR2696095B1 (en) * | 1992-09-30 | 1994-11-25 | Inoteb | Biological glue based on proteins coagulable by thrombin, enriched in platelet factors, its preparation and its application. |
US5330974A (en) * | 1993-03-01 | 1994-07-19 | Fibratek, Inc. | Therapeutic fibrinogen compositions |
US5552452A (en) * | 1993-03-15 | 1996-09-03 | Arch Development Corp. | Organic tissue glue for closure of wounds |
FR2705235B1 (en) * | 1993-05-13 | 1995-07-13 | Inoteb | Use of particles of a biocompatible and bioresorbable calcium salt as an active ingredient in the preparation of a medicament for the local treatment of demineralizing bone diseases. |
US5759194A (en) * | 1993-09-28 | 1998-06-02 | Hemodynamics, Inc. | Vascular patch applicator |
US5843124A (en) | 1993-09-28 | 1998-12-01 | Hemodynamics, Inc. | Surface opening adhesive sealer |
US5653730A (en) * | 1993-09-28 | 1997-08-05 | Hemodynamics, Inc. | Surface opening adhesive sealer |
EP0726749B1 (en) * | 1993-11-03 | 2004-08-11 | Clarion Pharmaceuticals, Inc. | Hemostatic patch |
US5411885A (en) * | 1993-12-17 | 1995-05-02 | New York Blood Center, Inc. | Methods for tissue embedding and tissue culturing |
US5639940A (en) | 1994-03-03 | 1997-06-17 | Pharmaceutical Proteins Ltd. | Production of fibrinogen in transgenic animals |
DE758903T1 (en) * | 1994-03-31 | 1997-07-10 | Fibrin Corp | CONCENTRATES OF CRYOPRECIPTED, NATURAL FIBRINOGEN |
US5583114A (en) | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
USRE38827E1 (en) | 1994-07-27 | 2005-10-11 | 3M Innovative Properties Company | Adhesive sealant composition |
US5660873A (en) * | 1994-09-09 | 1997-08-26 | Bioseal, Limited Liability Corporaton | Coating intraluminal stents |
DE69533188T2 (en) * | 1994-10-11 | 2005-02-17 | Ajinomoto Co., Inc. | STABILIZED TRANSGLUTAMINASE AND ENZYMATIC PREPARATION CONTAINING THEREOF |
US5464471A (en) * | 1994-11-10 | 1995-11-07 | Whalen Biomedical Inc. | Fibrin monomer based tissue adhesive |
US5585007A (en) | 1994-12-07 | 1996-12-17 | Plasmaseal Corporation | Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant |
ATE244584T1 (en) * | 1995-01-16 | 2003-07-15 | Baxter Int | SELF-SUPPORTING SURFACES MADE OF CROSS-LINKED FIBRIN FOR INHIBITING POSTOPERATIVE ADHESIONS |
US5733545A (en) * | 1995-03-03 | 1998-03-31 | Quantic Biomedical Partners | Platelet glue wound sealant |
US5674394A (en) * | 1995-03-24 | 1997-10-07 | Johnson & Johnson Medical, Inc. | Single use system for preparation of autologous plasma |
US5643192A (en) * | 1995-04-06 | 1997-07-01 | Hamilton Civic Hospitals Research Development, Inc. | Autologous fibrin glue and methods for its preparation and use |
CA2222506C (en) * | 1995-06-06 | 2007-07-24 | Quantic Biomedical Partners | Device and method for concentrating plasma |
DE19521324C1 (en) * | 1995-06-12 | 1996-10-31 | Immuno Ag | Tissue adhesive and use thereof as a hemostatic |
US5733884A (en) * | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
ATE309006T1 (en) | 1996-03-15 | 2005-11-15 | Chemo Sero Therapeut Res Inst | SPRAY DEVICE FOR APPLYING FABRIC ADHESIVE |
WO2000062828A1 (en) | 1996-04-30 | 2000-10-26 | Medtronic, Inc. | Autologous fibrin sealant and method for making the same |
DE19617369A1 (en) * | 1996-04-30 | 1997-11-06 | Immuno Ag | Storage-stable fibrinogen preparations |
AU3720097A (en) | 1996-07-12 | 1998-02-09 | Baxter International Inc. | A fibrin delivery device and method for forming fibrin on a surface |
US8303981B2 (en) | 1996-08-27 | 2012-11-06 | Baxter International Inc. | Fragmented polymeric compositions and methods for their use |
US6066325A (en) | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US8603511B2 (en) | 1996-08-27 | 2013-12-10 | Baxter International, Inc. | Fragmented polymeric compositions and methods for their use |
US7435425B2 (en) | 2001-07-17 | 2008-10-14 | Baxter International, Inc. | Dry hemostatic compositions and methods for their preparation |
US8003705B2 (en) | 1996-09-23 | 2011-08-23 | Incept Llc | Biocompatible hydrogels made with small molecule precursors |
AU4648697A (en) * | 1996-09-23 | 1998-04-14 | Chandrashekar Pathak | Methods and devices for preparing protein concentrates |
US6566406B1 (en) * | 1998-12-04 | 2003-05-20 | Incept, Llc | Biocompatible crosslinked polymers |
US7009034B2 (en) * | 1996-09-23 | 2006-03-07 | Incept, Llc | Biocompatible crosslinked polymers |
US20090324721A1 (en) | 1996-09-23 | 2009-12-31 | Jack Kennedy | Hydrogels Suitable For Use In Polyp Removal |
FR2757770B1 (en) * | 1996-12-30 | 1999-02-26 | Inoteb | PROCESS FOR THE PREPARATION OF A BIOLOGICAL GLUE CAPABLE OF COAGULATING BY SIMPLE ADDITION OF CALCIUM IONS |
AU7977298A (en) | 1997-06-18 | 1999-01-04 | Cohesion Technologies, Inc. | Compositions containing thrombin and microfibrillar collagen, and methods for preparation and use thereof |
AT406120B (en) | 1997-08-28 | 2000-02-25 | Immuno Ag | TISSUE ADHESIVE |
DE19755023C2 (en) * | 1997-12-11 | 2000-03-09 | Celanese Chem Europe Gmbh | Catalyst and process for making vinyl acetate |
US6762336B1 (en) | 1998-01-19 | 2004-07-13 | The American National Red Cross | Hemostatic sandwich bandage |
US6884230B1 (en) | 1998-03-09 | 2005-04-26 | Baxter International Inc. | Dispensing head for a tissue sealant applicator and process of use |
US6274090B1 (en) | 1998-08-05 | 2001-08-14 | Thermogenesis Corp. | Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby |
US6994686B2 (en) * | 1998-08-26 | 2006-02-07 | Neomend, Inc. | Systems for applying cross-linked mechanical barriers |
US6921380B1 (en) | 1998-10-01 | 2005-07-26 | Baxter International Inc. | Component mixing catheter |
US7279001B2 (en) * | 1998-11-06 | 2007-10-09 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
DE69941498D1 (en) | 1998-11-12 | 2009-11-12 | Internat Mfg Group Inc | Hemostatic cross-linked dextran beads useful for rapid blood clotting and hemostasis |
US6310036B1 (en) | 1999-01-09 | 2001-10-30 | Last Chance Tissue Adhesives Corporation | High strength, Bio-compatible tissue adhesive and methods for treating vigorously bleeding surfaces |
US8556967B2 (en) * | 1999-04-09 | 2013-10-15 | Faezeh Mona Sarfarazi | Interior bag for a capsular bag and injector |
US7662179B2 (en) * | 1999-04-09 | 2010-02-16 | Sarfarazi Faezeh M | Haptics for accommodative intraocular lens system |
US20030007954A1 (en) | 1999-04-12 | 2003-01-09 | Gail K. Naughton | Methods for using a three-dimensional stromal tissue to promote angiogenesis |
US6472162B1 (en) | 1999-06-04 | 2002-10-29 | Thermogenesis Corp. | Method for preparing thrombin for use in a biological glue |
US6916911B1 (en) | 1999-08-13 | 2005-07-12 | Omrix Biopharmaceuticals Sa | Use of fibrinogen multimers |
WO2001012244A1 (en) * | 1999-08-13 | 2001-02-22 | Omrix Biopharmaceuticals S.A. | Use of fibrinogen multimers |
US7078232B2 (en) * | 1999-08-19 | 2006-07-18 | Artecel, Inc. | Adipose tissue-derived adult stem or stromal cells for the repair of articular cartilage fractures and uses thereof |
US6429013B1 (en) | 1999-08-19 | 2002-08-06 | Artecel Science, Inc. | Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair |
US6463335B1 (en) | 1999-10-04 | 2002-10-08 | Medtronic, Inc. | Temporary medical electrical lead having electrode mounting pad with biodegradable adhesive |
US6960463B2 (en) * | 1999-12-23 | 2005-11-01 | Csl Limited | Separation of fibrinogen from plasma proteases |
EP1301245A4 (en) * | 2000-07-17 | 2007-02-28 | Haemacure Corp | Spray head for applying a multi-component mixture |
WO2002030445A2 (en) * | 2000-10-13 | 2002-04-18 | Baxter International Inc. | Fibrinogen plus a non-plasmin-acting fibrinolysis inhibitor for the reduction or prevention of adhesion formation |
US6648911B1 (en) | 2000-11-20 | 2003-11-18 | Avantec Vascular Corporation | Method and device for the treatment of vulnerable tissue site |
US20020082620A1 (en) * | 2000-12-27 | 2002-06-27 | Elaine Lee | Bioactive materials for aneurysm repair |
US6468660B2 (en) | 2000-12-29 | 2002-10-22 | St. Jude Medical, Inc. | Biocompatible adhesives |
US7175336B2 (en) | 2001-01-26 | 2007-02-13 | Depuy Acromed, Inc. | Graft delivery system |
US7795218B2 (en) | 2001-04-12 | 2010-09-14 | Bioaxone Therapeutique Inc. | ADP-ribosyl transferase fusion variant proteins |
US20020173770A1 (en) * | 2001-05-16 | 2002-11-21 | Flory Alan R. | Adhesive delivery system |
AU2002361902A1 (en) | 2001-12-31 | 2003-07-24 | Ares Medical, Inc. | Hemostatic compositions and methods for controlling bleeding |
US20030205538A1 (en) | 2002-05-03 | 2003-11-06 | Randel Dorian | Methods and apparatus for isolating platelets from blood |
US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
US7374678B2 (en) | 2002-05-24 | 2008-05-20 | Biomet Biologics, Inc. | Apparatus and method for separating and concentrating fluids containing multiple components |
US7992725B2 (en) | 2002-05-03 | 2011-08-09 | Biomet Biologics, Llc | Buoy suspension fractionation system |
US7845499B2 (en) | 2002-05-24 | 2010-12-07 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
DE10392686T5 (en) | 2002-05-24 | 2005-07-07 | Biomet Mfg. Corp., Warsaw | Apparatus and method for separating and concentrating liquids containing multiple components |
US20060278588A1 (en) | 2002-05-24 | 2006-12-14 | Woodell-May Jennifer E | Apparatus and method for separating and concentrating fluids containing multiple components |
JP4777650B2 (en) * | 2002-09-10 | 2011-09-21 | アメリカン ナショナル レッド クロス | Hemostatic bandage |
US7135027B2 (en) | 2002-10-04 | 2006-11-14 | Baxter International, Inc. | Devices and methods for mixing and extruding medically useful compositions |
US8834864B2 (en) | 2003-06-05 | 2014-09-16 | Baxter International Inc. | Methods for repairing and regenerating human dura mater |
US7927626B2 (en) * | 2003-08-07 | 2011-04-19 | Ethicon, Inc. | Process of making flowable hemostatic compositions and devices containing such compositions |
US20050125033A1 (en) * | 2003-12-04 | 2005-06-09 | Mcnally-Heintzelman Karen M. | Wound closure apparatus |
US20050125015A1 (en) * | 2003-12-04 | 2005-06-09 | Mcnally-Heintzelman Karen M. | Tissue-handling apparatus, system and method |
TWI270375B (en) * | 2004-06-29 | 2007-01-11 | Cheng-Yao Su | A method for preserving platelets outside a living body |
US7659052B2 (en) * | 2004-06-29 | 2010-02-09 | Cheng Yao Su | Medium comprising cryoprecipitate and method for preserving platelets, red blood cells and other cells without a nucleus |
EP1763552A1 (en) * | 2004-07-08 | 2007-03-21 | Symatese | Collagen-based lyophilised glue and the use thereof for producing an adhesive prosthesis |
WO2006021584A2 (en) * | 2004-08-27 | 2006-03-02 | Novo Nordisk Health Care Ag | Purification of factor xiii polypeptides from biological materials |
ATE550423T1 (en) * | 2004-08-30 | 2012-04-15 | Theregen Inc | THREE-DIMENSIONAL CULTIVATED TISSUES AND THEIR USE |
US20080226604A9 (en) * | 2005-06-17 | 2008-09-18 | Theregen Company | Methods for treating ischemic tissue |
ATE540974T1 (en) | 2004-11-23 | 2012-01-15 | Zymogenetics Inc | PURIFICATION OF RECOMBINANT HUMAN FACTOR XIII |
EP1848474B1 (en) | 2005-02-07 | 2013-06-12 | Hanuman LLC | Platelet rich plasma concentrate apparatus and method |
US7866485B2 (en) | 2005-02-07 | 2011-01-11 | Hanuman, Llc | Apparatus and method for preparing platelet rich plasma and concentrates thereof |
WO2006086199A1 (en) | 2005-02-07 | 2006-08-17 | Hanuman Llc | Platelet rich plasma concentrate apparatus and method |
AU2006213822B2 (en) | 2005-02-09 | 2011-05-26 | Covidien Lp | Synthetic sealants |
TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
US20060212106A1 (en) * | 2005-03-21 | 2006-09-21 | Jan Weber | Coatings for use on medical devices |
FR2887883B1 (en) | 2005-06-29 | 2007-08-31 | Lab Francais Du Fractionnement | PROCESS FOR SEPARATING FIBRINOGEN PROTEINS, FACTOR XIII AND BIOLOGICAL GLUE OF SOLUBILIZED PLASMA FRONTION AND PREPARATION OF LYOPHILIZED CONCENTRATES OF SAID PROTEINS |
FR2894831B1 (en) | 2005-12-16 | 2008-02-15 | Lab Francais Du Fractionnement | THROMBIN FREE BIOLOGICAL GLUE AND USE THEREOF AS MEDICAMENT. |
US8567609B2 (en) | 2006-05-25 | 2013-10-29 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
CN101454030B (en) | 2006-05-31 | 2013-06-26 | 巴克斯特国际公司 | Method for directed cell in-growth and controlled tissue regeneration in spinal surgery |
TWI436793B (en) | 2006-08-02 | 2014-05-11 | Baxter Int | Rapidly acting dry sealant and methods for use and manufacture |
KR20090038025A (en) | 2006-08-02 | 2009-04-17 | 코리오닉스 | Implantable preparation, useful more particularly for tissue complement and cicatrisation |
WO2008019128A2 (en) * | 2006-08-04 | 2008-02-14 | Stb Lifesaving Technologies, Inc. | Solid dressing for treating wounded tissue |
WO2008033417A2 (en) * | 2006-09-13 | 2008-03-20 | Southeastern Medical Technologies, Llc | Methods and compositions for sealing and adhering biological tissues and medical uses thereof |
US20090227981A1 (en) * | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
US20090227689A1 (en) * | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
KR20090122279A (en) | 2007-03-22 | 2009-11-26 | 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | Solid fibrinogen preparation |
US8328024B2 (en) | 2007-04-12 | 2012-12-11 | Hanuman, Llc | Buoy suspension fractionation system |
JP5479319B2 (en) | 2007-04-12 | 2014-04-23 | バイオメット・バイオロジックス・リミテッド・ライアビリティ・カンパニー | Buoy suspension fractionation system |
WO2009020612A1 (en) * | 2007-08-06 | 2009-02-12 | Stb Lifesaving Technologies, Inc. | Methods and dressing for sealing internal injuries |
JP2011500237A (en) | 2007-10-30 | 2011-01-06 | バクスター・インターナショナル・インコーポレイテッド | Use of regenerative biofunctional collagen biomatrix to treat visceral or cavity wall defects |
CN101214391B (en) * | 2007-12-27 | 2010-05-19 | 广州倍绣生物技术有限公司 | High-efficiency biogum sealant and uses thereof |
EP2567692B1 (en) | 2008-02-27 | 2016-04-06 | Biomet Biologics, LLC | Use of a device for obtaining interleukin-1 receptor antagonist rich solutions |
US8337711B2 (en) | 2008-02-29 | 2012-12-25 | Biomet Biologics, Llc | System and process for separating a material |
WO2009109194A2 (en) | 2008-02-29 | 2009-09-11 | Ferrosan A/S | Device for promotion of hemostasis and/or wound healing |
US8012077B2 (en) | 2008-05-23 | 2011-09-06 | Biomet Biologics, Llc | Blood separating device |
JP5292025B2 (en) * | 2008-09-09 | 2013-09-18 | 一般財団法人化学及血清療法研究所 | Carboxylic acid-containing biological tissue adhesive and preparation method thereof |
AR081227A1 (en) | 2008-12-11 | 2012-07-18 | Baxter Int | PREPARATIONS BASED ON SULFATED FIBRINOGENS AND POLISACARIDS |
US8409606B2 (en) * | 2009-02-12 | 2013-04-02 | Incept, Llc | Drug delivery through hydrogel plugs |
US8187475B2 (en) | 2009-03-06 | 2012-05-29 | Biomet Biologics, Llc | Method and apparatus for producing autologous thrombin |
US8313954B2 (en) | 2009-04-03 | 2012-11-20 | Biomet Biologics, Llc | All-in-one means of separating blood components |
US9039783B2 (en) | 2009-05-18 | 2015-05-26 | Baxter International, Inc. | Method for the improvement of mesh implant biocompatibility |
PT2442835E (en) | 2009-06-16 | 2015-03-23 | Baxter Healthcare Sa | Hemostatic sponge |
US9011800B2 (en) | 2009-07-16 | 2015-04-21 | Biomet Biologics, Llc | Method and apparatus for separating biological materials |
WO2011035020A1 (en) | 2009-09-18 | 2011-03-24 | Bioinspire Technologies, Inc. | Free-standing biodegradable patch |
US9271925B2 (en) | 2013-03-11 | 2016-03-01 | Bioinspire Technologies, Inc. | Multi-layer biodegradable device having adjustable drug release profile |
FR2952641B1 (en) | 2009-11-18 | 2012-01-13 | Lfb Biomedicaments | PROCESS FOR TREATING BLOOD PLASMA COMPRISING A DISPERSION WASH STEP |
JP2013514093A (en) | 2009-12-16 | 2013-04-25 | バクスター・インターナショナル・インコーポレイテッド | Hemostatic sponge |
SA111320355B1 (en) | 2010-04-07 | 2015-01-08 | Baxter Heathcare S A | Hemostatic sponge |
US8591391B2 (en) | 2010-04-12 | 2013-11-26 | Biomet Biologics, Llc | Method and apparatus for separating a material |
US9084728B2 (en) | 2010-06-01 | 2015-07-21 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
CN103037845B (en) | 2010-06-01 | 2015-11-25 | 巴克斯特国际公司 | For the preparation of the method for dry, stable hemostatic composition |
JP6289096B2 (en) | 2010-06-01 | 2018-03-07 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Process for making a dry and stable hemostatic composition |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
AU2012318257B2 (en) | 2011-10-11 | 2015-10-01 | Baxter Healthcare S.A. | Hemostatic compositions |
US20130090291A1 (en) | 2011-10-11 | 2013-04-11 | Baxter Healthcare S.A. | Hemostatic compositions |
US20130108671A1 (en) | 2011-10-27 | 2013-05-02 | Baxter Healthcare S.A. | Hemostatic compositions |
JP6241624B2 (en) | 2012-03-06 | 2017-12-06 | フェロサン メディカル デバイシーズ エイ/エス | Pressurized container containing hemostatic paste |
JP6394916B2 (en) | 2012-06-12 | 2018-09-26 | フェロサン メディカル デバイシーズ エイ/エス | Dry hemostatic composition |
US9642956B2 (en) | 2012-08-27 | 2017-05-09 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
AU2014283170B2 (en) | 2013-06-21 | 2017-11-02 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
CA2928963C (en) | 2013-12-11 | 2020-10-27 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
JP6726852B2 (en) | 2014-10-13 | 2020-07-22 | フェッローサン メディカル ディバイス エー/エス | Dry composition for use in hemostasis and wound healing |
JP6747650B2 (en) | 2014-12-24 | 2020-08-26 | フェロサン メディカル デバイシーズ エイ/エス | Syringe for holding and mixing the first substance and the second substance |
US9713810B2 (en) | 2015-03-30 | 2017-07-25 | Biomet Biologics, Llc | Cell washing plunger using centrifugal force |
US9757721B2 (en) | 2015-05-11 | 2017-09-12 | Biomet Biologics, Llc | Cell washing plunger using centrifugal force |
CA2986981A1 (en) | 2015-07-03 | 2017-01-12 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
JP7395113B2 (en) | 2018-05-09 | 2023-12-11 | フェロサン メディカル デバイシーズ エイ/エス | Method of preparing a hemostatic composition |
US20230210958A1 (en) | 2021-12-30 | 2023-07-06 | Baxter International Inc. | Fibrinogen and thrombin solutions for a fibrin sealant and fibrin sealant kit |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA448302A (en) * | 1948-05-04 | Joseph Cohn Edwin | Plastic product and process | |
GB1195061A (en) * | 1966-05-27 | 1970-06-17 | Fmc Corp | Coated Structures and Methods of Forming Them. |
US3523807A (en) * | 1966-11-25 | 1970-08-11 | Mihaly Gerendas | Method of making a cross-linked fibrin prosthesis |
US4265233A (en) * | 1978-04-12 | 1981-05-05 | Unitika Ltd. | Material for wound healing |
AT359652B (en) * | 1979-02-15 | 1980-11-25 | Immuno Ag | METHOD FOR PRODUCING A TISSUE ADHESIVE |
-
1979
- 1979-02-15 AT AT118979A patent/AT359652B/en not_active IP Right Cessation
-
1980
- 1980-01-21 SE SE8000469A patent/SE453799C/en not_active IP Right Cessation
- 1980-01-28 DE DE3002934A patent/DE3002934C2/en not_active Expired
- 1980-01-30 CA CA344,717A patent/CA1128859A/en not_active Expired
- 1980-01-31 FR FR8002165A patent/FR2448900A1/en active Granted
- 1980-01-31 BE BE0/199200A patent/BE881466A/en not_active IP Right Cessation
- 1980-02-04 US US06/118,529 patent/US4362567A/en not_active Expired - Lifetime
- 1980-02-05 GB GB8003775A patent/GB2041942B/en not_active Expired
- 1980-02-08 ES ES488430A patent/ES8101381A1/en not_active Expired
- 1980-02-08 JP JP1378280A patent/JPS55110556A/en active Granted
- 1980-02-13 CH CH1174/80A patent/CH649711A5/en not_active IP Right Cessation
- 1980-02-14 NL NLAANVRAGE8000935,A patent/NL190714B/en not_active Application Discontinuation
- 1980-02-14 IT IT19910/80A patent/IT1141211B/en active
- 1980-02-15 DK DK065580AA patent/DK150815B/en not_active IP Right Cessation
-
1982
- 1982-09-13 US US06/417,538 patent/US4414976A/en not_active Expired - Lifetime
-
1989
- 1989-06-30 SE SE8902377A patent/SE462613B/en not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5290918A (en) * | 1993-02-23 | 1994-03-01 | Haemacure Biotech Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation |
US5395923A (en) * | 1993-02-23 | 1995-03-07 | Haemacure-Biotech, Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out" |
Also Published As
Publication number | Publication date |
---|---|
DE3002934A1 (en) | 1980-08-28 |
BE881466A (en) | 1980-05-16 |
US4414976A (en) | 1983-11-15 |
ES488430A0 (en) | 1980-12-16 |
ATA118979A (en) | 1980-04-15 |
GB2041942A (en) | 1980-09-17 |
DK150815B (en) | 1987-06-29 |
DK65580A (en) | 1980-08-16 |
SE8902377D0 (en) | 1989-06-30 |
JPS55110556A (en) | 1980-08-26 |
NL8000935A (en) | 1980-08-19 |
SE453799B (en) | 1988-03-07 |
SE8000469L (en) | 1980-08-16 |
DE3002934C2 (en) | 1983-12-29 |
ES8101381A1 (en) | 1980-12-16 |
JPS6340546B2 (en) | 1988-08-11 |
AT359652B (en) | 1980-11-25 |
GB2041942B (en) | 1983-04-13 |
US4362567A (en) | 1982-12-07 |
SE462613B (en) | 1990-07-30 |
IT8019910A0 (en) | 1980-02-14 |
FR2448900A1 (en) | 1980-09-12 |
IT1141211B (en) | 1986-10-01 |
CH649711A5 (en) | 1985-06-14 |
NL190714B (en) | 1994-02-16 |
SE453799C (en) | 1998-03-20 |
FR2448900B1 (en) | 1984-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1128859A (en) | Tissue adhesive | |
CA1119516A (en) | Tissue adhesive | |
CA2113660C (en) | Process for the obtention of biological adhesive made of concentrated coagulation factors by salting-out | |
US5260420A (en) | Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof | |
KR100197930B1 (en) | Fibrin sealant delivery method | |
CA1168982A (en) | Tissue adhesive | |
EP0602173B1 (en) | Topical fibrinogen complex | |
JP3367698B2 (en) | Stable fibrinogen solution | |
JPS5838216A (en) | Condensed blood plasma derivative | |
US4621631A (en) | Process for the production of a bonded collagen fiber sheet | |
JP2896235B2 (en) | Topical fibrinogen complex | |
NZ203164A (en) | Solid fibrinogen formulation | |
EP1043034A1 (en) | Adhesive for biological tissue | |
US10456500B2 (en) | Implantable preparations for regeneration of tissues and treatment of wounds, their method of preparation, and method of treatment of patients with said implantable preparations | |
JPH02114A (en) | Contentrate of tropine coagulable protein, its production and use thereof in treatment | |
JPH02129224A (en) | Preparation of fibrin | |
AU727822B2 (en) | Compositions useful as fibrin sealants | |
FI96918B (en) | Composition for stabilizing blood plasma during pasteurization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |